Cecilia de Leeuw brings broad international experience from her prior leadership roles in Global Product Management, Product Commercialization and Global Sales, as well as heading up key accounts in North America and the Nordics.

“I am honored to be the CEO of this exciting company with competitive products and an impressive global reach. C-RAD employees, partners and customers are at the forefront of contributing to the growing recognition of surface tracking and together we will ensure SGRT is the standard of care for all patients and their clinical staff,” states Cecilia de Leeuw

Cecilia succeeds Tim Thurn, who is leaving his position after almost ten years as CEO. Under Tim’s leadership, C-RAD successfully transformed from a medical technology start-up company to a respected global partner in SGRT for precision, efficiency and safety for advanced cancer care.

Cecilia de Leeuw adds, “We have an important job: to improve the lives of cancer patients around the world with the help from C-RAD’s leading technologies.”

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient’s motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit https://www.c-rad.com

For further information:
Lars Nyberg, Chairman of the Board of C-RAD AB, Email investors@c-rad.com